Research Interests
The long-term goal of my lab is to develop immunotherapies for leukemia and other hematological diseases through an understanding of T-cell immunity against hematopoietic progenitors. Our central hypothesis is that T-cells target and eliminate these progenitors by recognizing determinants of self-antigens when tolerance has been reversed by aberrant self-antigen expression. As models, we have studied myeloid leukemia and MDS and have found that CD8 lymphocytes recognized the HLA-A2-restricted PR1 peptide, derived from both P3 and NE, due to aberrant subcellular localization and over-expression.